Connect with us

Health

World Health Organization Certifies Thailand’s Anti-Retrovirus HIV Drug Efavirenz

Published

on

BANGKOK – The World Health Organization has certified the Government Pharmaceutical Organization’s anti-retrovirus HIV drug Efavirenz, and the GPO is now looking to overseas sales.

GPO chairman Sopon Mekthon said on Friday that Efavirenz is the first drug developed in Thailand and Asean to pass the WHO Pre-qualification Program and be included in the WHO’s pre-qualified list.

Consequently, international health organizations such as the Global Fund and Unicef can order the medication for use in underdeveloped countries, he said.

 

Efavirenz is the medication prescribed to all HIV-infected people when they are first diagnosed with the virus, Dr Sopon said.

Mukdavan Prakobvaitayakit, deputy managing director of the GPO, said the organization had taken 16 years to develop the drug, which has the same properties as the prototype medication. The anti-retro viral agent had passed the WHO’s meticulous examination.

The locally made product is marketed at 180 baht per bottle of 30 600mg tablets, while the imported product retails at more than 1,000 baht per bottle, she said.

After the WHO’s certification, many countries asked the GPO to register the medication there so they could order it, Ms Mukdavan said.

She cited the Philippines and Caribbean countries as examples. The Philippines planned to order about 300,000 bottles at a cost of 51 million baht, she said.

The GPO would produce 42 million Efavirenz tablets this year. This amount accounted for only 2.5% of the total capacity of the GPO, she said.

By Tawatchai Kemgumnerd